{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T16:16:22Z","timestamp":1791994582248,"version":"4.4.0"},"reference-count":27,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"},{"start":{"date-parts":[[2022,9,6]],"date-time":"2022-09-06T00:00:00Z","timestamp":1662422400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,12,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Checkpoint inhibitor (CPI) therapy has significantly improved overall survival in several cancers including metastatic melanoma (MM) and in the adjuvant setting. Cutaneous immune-related adverse events (irAEs) secondary to CPIs are commonly observed; however, autoimmune blistering disorders such as bullous pemphigoid (BP) are rare.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>To review the prevalence, incidence risk, clinicopathological features and management of toxicity in bullous cutaneous irAEs associated with CPI therapy.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>A multicentre, retrospective, observational study of CPI-associated bullous irAEs in adults with all cancers across four UK specialist centres between 2006 and 2019.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>In total, 7391 patients were identified. CPI-associated bullous irAEs including BP (n = 16) occurred in 0\u00b73% (n = 22). The median age of onset was 76 years, and there was a male predominance. Most patients had cutaneous melanoma (73%, n = 16), of which 81% (13 of 16) were BRAF wildtype. Grade 1, 2, 3 and 4 skin toxicity occurred in 9%, 45%, 41% and 5%, respectively. The mucosae were involved in 27%, and 25% of confirmed cases of BP did not present with bullae. The median time to onset of bullous irAEs was 12 months, with a median total symptom duration of 6 months. Single PD-1\/PD-L1 agents had a longer time to onset of symptoms than combination therapy (median 12 vs. 7 months, respectively). Overall, 91%, 64% and 9% of patients required one, two or three lines of treatment, respectively. Two cases occurred after completion of CPIs (1 and 3 months). Of the 20 cases that presented while on CPIs this was permanently discontinued in 55% (11 of 20) and temporarily held in 20% (four of 20). In the four held cases of CPI, bullous eruption reflared in 50%.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>CPI-associated bullous skin toxicity is a rare cutaneous irAE occurring in approximately 0\u00b73% of cases over 13 years of treated patients in this series. Not all cases are diagnostic of BP, but management remains the same. There is a prolonged latency of onset compared with other cutaneous irAEs, with a median time of 12 months, and they can occur after cessation of therapy. Discontinuation of CPIs may be required. Recognizing bullous irAEs promptly and referral to dermatology are essential to optimize management and improve patient outcomes and tumour responses.<\/jats:p>\n                  <jats:p>What is already known about this topic? \u00a0Checkpoint inhibitor (CPI)-associated bullous pemphigoid is a rare dermatological immune-related adverse event (irAE) that has been reported in small case series and reports.<\/jats:p>\n                  <jats:p>What does this study add? \u00a0This is the largest multicentre, observational study conducted in the UK over the longest period of 13 years, which demonstrates an overall incidence of bullous cutaneous irAEs secondary to CPIs of 0\u00b73%.Clinical presentation is variable, with one-quarter of patients with bullous pemphigoid presenting without bullae, and mucosal involvement was noted in 27%. Prolonged pruritus is frequently a prodromal symptom.The median time to diagnosis is 12 months and irAEs rarely present after cessation of treatment. Time to onset of symptoms is longer with a single CPI, but with a shorter duration of symptoms compared with combination CPI therapy.Most patients had cutaneous melanoma, of which 81% were BRAF wildtype.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1111\/bjd.21836","type":"journal-article","created":{"date-parts":[[2022,8,17]],"date-time":"2022-08-17T14:30:19Z","timestamp":1660746619000},"page":"981-987","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":52,"title":["Checkpoint inhibitor-associated bullous cutaneous immune-related adverse events: a multicentre observational study"],"prefix":"10.1093","volume":"187","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7065-1779","authenticated-orcid":false,"given":"Anusuya","family":"Kawsar","sequence":"first","affiliation":[{"name":"Department of Dermatology Chelsea and Westminster Hospital NHS Foundation Trust London UK"},{"name":"Department of Dermatology The Royal Marsden Hospital NHS Foundation Trust London UK"},{"name":"Department of Dermatology Barts Health NHS Trust, Royal London Hospital London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3401-1002","authenticated-orcid":false,"given":"Charlotte","family":"Edwards","sequence":"additional","affiliation":[{"name":"Department of Dermatology Chelsea and Westminster Hospital NHS Foundation Trust London UK"},{"name":"Department of Dermatology The Royal Marsden Hospital NHS Foundation Trust London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2268-7021","authenticated-orcid":false,"given":"Pooja","family":"Patel","sequence":"additional","affiliation":[{"name":"Department of Dermatology Barts Health NHS Trust, Royal London Hospital London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard M.","family":"Heywood","sequence":"additional","affiliation":[{"name":"Department of Oncology The Christie NHS Foundation Trust Manchester UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aakriti","family":"Gupta","sequence":"additional","affiliation":[{"name":"Department of Dermatology Oxford University Hospitals NHS Foundation Trust Oxford UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8207-5350","authenticated-orcid":false,"given":"Jasmine","family":"Mann","sequence":"additional","affiliation":[{"name":"Department of Dermatology The Royal Marsden Hospital NHS Foundation Trust London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Harland","sequence":"additional","affiliation":[{"name":"Department of Dermatology The Royal Marsden Hospital NHS Foundation Trust London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kara","family":"Heelan","sequence":"additional","affiliation":[{"name":"Department of Dermatology The Royal Marsden Hospital NHS Foundation Trust London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5569-9523","authenticated-orcid":false,"given":"James","family":"Larkin","sequence":"additional","affiliation":[{"name":"Department of Dermatology The Royal Marsden Hospital NHS Foundation Trust London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8875-2164","authenticated-orcid":false,"given":"Paul","family":"Lorigan","sequence":"additional","affiliation":[{"name":"Department of Oncology The Christie NHS Foundation Trust Manchester UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1375-0965","authenticated-orcid":false,"given":"Catherine A.","family":"Harwood","sequence":"additional","affiliation":[{"name":"Department of Dermatology Barts Health NHS Trust, Royal London Hospital London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9695-5412","authenticated-orcid":false,"given":"Rubeta N.","family":"Matin","sequence":"additional","affiliation":[{"name":"Department of Dermatology Oxford University Hospitals NHS Foundation Trust Oxford UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1122-4216","authenticated-orcid":false,"given":"Louise","family":"Fearfield","sequence":"additional","affiliation":[{"name":"Department of Dermatology Chelsea and Westminster Hospital NHS Foundation Trust London UK"},{"name":"Department of Dermatology The Royal Marsden Hospital NHS Foundation Trust London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2022,12,1]]},"reference":[{"key":"2023010808112400200_bjd21836-bib-0001","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1056\/NEJMoa1910836","article-title":"Five-year survival with combined nivolumab and ipilimumab in advanced melanoma","volume":"381","author":"Larkin","year":"2019","journal-title":"N Engl J Med"},{"key":"2023010808112400200_bjd21836-bib-0002","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1016\/S1470-2045(20)30494-0","article-title":"Adjuvant nivolumab versus ipilimumab in resected stage IIIB-C and stage IV melanoma: 4-year results from a multicentre, double-blind, randomised, controlled, phase 3 trial","volume":"21","author":"Ascierto","year":"2020","journal-title":"Lancet Oncol"},{"key":"2023010808112400200_bjd21836-bib-0003","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1097\/CMR.0000000000000500","article-title":"Anti-programmed cell death-1 therapy-associated bullous disorders: a systematic review of the literature","volume":"28","author":"Zhao","year":"2018","journal-title":"Melanoma Res"},{"key":"2023010808112400200_bjd21836-bib-0004","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1111\/ced.14469","article-title":"Cutaneous toxicities in patients with melanoma receiving checkpoint inhibitor therapy: a retrospective review. The experience of a single large specialist institution","volume":"46","author":"Edwards","year":"2021","journal-title":"Clin Exp Dermatol"},{"key":"2023010808112400200_bjd21836-bib-0005","doi-asserted-by":"crossref","first-page":"e183","DOI":"10.1111\/ijd.14811","article-title":"Stevens\u2013Johnson syndrome and toxic epidermal necrolysis-like reactions to checkpoint inhibitors: a systematic review","volume":"59","author":"Maloney","year":"2020","journal-title":"Int J Dermatol"},{"key":"2023010808112400200_bjd21836-bib-0006","first-page":"1621","article-title":"Drug eruptions with novel targeted therapies \u2013 immune checkpoint and EGFR inhibitors","volume":"19","author":"Pospischil","year":"2021","journal-title":"J Dtsch Dermatol Ges"},{"key":"2023010808112400200_bjd21836-bib-0007","author":"US Department of Health and Human Services"},{"key":"2023010808112400200_bjd21836-bib-0008","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1016\/j.jaad.2018.07.008","article-title":"Bullous disorders associated with anti-PD-1 and anti-PD-L1 therapy: a retrospective analysis evaluating the clinical and histopathologic features, frequency, and impact on cancer therapy","volume":"79","author":"Siegel","year":"2018","journal-title":"J Am Acad Dermatol"},{"issue":"adv00377","key":"2023010808112400200_bjd21836-bib-0009","article-title":"Bullous pemphigoid associated with anti-programmed cell death protein 1 and anti-programmed cell death ligand 1 therapy: a review of the literature","volume":"101","author":"Tsiogka","year":"2021","journal-title":"Acta Derm Venereol"},{"key":"2023010808112400200_bjd21836-bib-0010","doi-asserted-by":"crossref","first-page":"e511","DOI":"10.1111\/jdv.17253","article-title":"Clinical, biological and histological characteristics of bullous pemphigoid associated with anti-PD-1\/PD-L1 therapy: a national retrospective study","volume":"35","author":"Juzot","year":"2021","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2023010808112400200_bjd21836-bib-0011","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1111\/bjd.19022","article-title":"Incidence, prevalence and mortality of bullous pemphigoid in England 1998\u20132017: a population-based cohort study","volume":"184","author":"Persson","year":"2021","journal-title":"Br J Dermatol"},{"key":"2023010808112400200_bjd21836-bib-0012","doi-asserted-by":"crossref","first-page":"220","DOI":"10.3389\/fmed.2018.00220","article-title":"The growing incidence of bullous pemphigoid: overview and potential explanations","volume":"5","author":"Kridin","year":"2018","journal-title":"Front Med (Lausanne)"},{"key":"2023010808112400200_bjd21836-bib-0013","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.36823","article-title":"Association between sex and immune checkpoint inhibitor outcomes for patients with melanoma","volume":"4","author":"Jang","year":"2021","journal-title":"JAMA Netw Open"},{"key":"2023010808112400200_bjd21836-bib-0014","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1038\/s41467-020-15679-x","article-title":"Sex-associated molecular differences for cancer immunotherapy","volume":"11","author":"Ye","year":"2020","journal-title":"Nat Commun"},{"key":"2023010808112400200_bjd21836-bib-0015","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaad.2019.12.068","article-title":"Bullous pemphigoid after anti-PD-1 therapy: a retrospective case\u2013control study evaluating impact on tumor response and survival outcomes","author":"Nelson","year":"2022","journal-title":"J Am Acad Dermatol"},{"key":"2023010808112400200_bjd21836-bib-0016","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1159\/000491814","article-title":"BRAF V600 mutational status in melanoma correlates with cytologic features in fine-needle aspirate specimens","volume":"63","author":"Lee","year":"2019","journal-title":"Acta Cytol"},{"key":"2023010808112400200_bjd21836-bib-0017","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1016\/j.jid.2019.11.005","article-title":"Recent advances in understanding pemphigus and bullous pemphigoid","volume":"140","author":"Hammers","year":"2020","journal-title":"J Invest Dermatol"},{"key":"2023010808112400200_bjd21836-bib-0018","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1097\/COC.0000000000000239","article-title":"CTLA-4 and PD-1 pathways: similarities, differences, and implications of their inhibition","volume":"39","author":"Buchbinder","year":"2016","journal-title":"Am J Clin Oncol"},{"key":"2023010808112400200_bjd21836-bib-0019","first-page":"103","article-title":"Bullous pemphigoid associated with a new combination checkpoint inhibitor immunotherapy","volume":"18","author":"Fontecilla","year":"2019","journal-title":"J Drugs Dermatol"},{"key":"2023010808112400200_bjd21836-bib-0020","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1634\/theoncologist.2018-0128","article-title":"A case of nivolumab-induced bullous pemphigoid: review of dermatologic toxicity associated with programmed cell death protein-1\/programmed death ligand-1 inhibitors and recommendations for diagnosis and management","volume":"23","author":"Lopez","year":"2018","journal-title":"Oncologist"},{"key":"2023010808112400200_bjd21836-bib-0021","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1097\/DAD.0000000000002139","article-title":"Lichen planus pemphigoides associated with PD-1 and PD-L1 inhibitors: a case series and review of the literature","volume":"44","author":"Boyle","year":"2022","journal-title":"Am J Dermatopathol"},{"key":"2023010808112400200_bjd21836-bib-0022","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1111\/cup.12717","article-title":"Autoimmune dermatologic toxicities from immune checkpoint blockade with anti-PD-1 antibody therapy: a report on bullous skin eruptions","volume":"43","author":"Jour","year":"2016","journal-title":"J Cutan Pathol"},{"key":"2023010808112400200_bjd21836-bib-0023","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.ejca.2020.07.026","article-title":"Role of the gut microbiome for cancer patients receiving immunotherapy: dietary and treatment implications","volume":"138","author":"Lee","year":"2020","journal-title":"Eur J Cancer"},{"key":"2023010808112400200_bjd21836-bib-0024","doi-asserted-by":"crossref","DOI":"10.1001\/jamadermatol.2022.1624","article-title":"Association of bullous pemphigoid with immune checkpoint inhibitor therapy in patients with cancer: a systematic review","author":"Asdourian","year":"2022","journal-title":"JAMA Dermatol"},{"key":"2023010808112400200_bjd21836-bib-0025","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1111\/ijd.13984","article-title":"A review of bullous pemphigoid associated with PD-1 and PD-L1 inhibitors","volume":"57","author":"Lopez","year":"2018","journal-title":"Int J Dermatol"},{"key":"2023010808112400200_bjd21836-bib-0026","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1016\/j.annonc.2021.03.204","article-title":"Delayed immune-related adverse events with anti-PD-1-based immunotherapy in melanoma","volume":"32","author":"Owen","year":"2021","journal-title":"Ann Oncol"},{"key":"2023010808112400200_bjd21836-bib-0027","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1158\/2326-6066.CIR-15-0123","article-title":"Autoimmune bullous skin disorders with immune checkpoint inhibitors targeting PD-1 and PD-L1","volume":"4","author":"Naidoo","year":"2016","journal-title":"Cancer Immunol Res"}],"container-title":["British Journal of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bjd.21836","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/bjd.21836","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/bjd\/article-pdf\/187\/6\/981\/48529640\/bjd0981.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/bjd\/article-pdf\/187\/6\/981\/48529640\/bjd0981.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,14]],"date-time":"2023-02-14T14:14:29Z","timestamp":1676384069000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/bjd\/article\/187\/6\/981\/6972569"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,1]]},"references-count":27,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2022,12,1]]},"published-print":{"date-parts":[[2022,12,1]]}},"URL":"https:\/\/doi.org\/10.1111\/bjd.21836","relation":{},"ISSN":["1365-2133","0007-0963"],"issn-type":[{"value":"1365-2133","type":"electronic"},{"value":"0007-0963","type":"print"}],"subject":[],"published-other":{"date-parts":[[2022,12,1]]},"published":{"date-parts":[[2022,12,1]]},"assertion":[{"value":"2021-09-30","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-08-16","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-09-06","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}